Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

Bioequivalence: Overview

Bioequivalence: Overview

Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Emphysematous gastritis: a systematic review of reported cases exploring predictors of mortality.

Translational gastroenterology and hepatology·2026

Same author

Pandemic-Related Disruptions and Hepatocellular Carcinoma Surveillance in Safety-Net Settings.

JAMA network open·2026

Same author

Unrecognized Fibrosis Risk in MASLD: A Real-World Analysis and the Case for AI-Augmented Stratification.

Gastro hep advances·2026

Same author

Postoperative complications after liver transplantation: Are we making progress?

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025

Same author

Bowel Ischemia as a Rare Manifestation of Extracranial Moyamoya Disease: A Case Report.

The American journal of case reports·2025

Same author

Clinical risk factors for hepatocellular carcinoma in Southeast Louisiana: a matched case-control study.

Cancer causes & control : CCC·2025

Search research articles

Related Experiment Video

Updated: Sep 14, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

A Real-World Experience With Resmetirom: Tolerability and Access.

Sameera Shuaibi¹, Ian Tobal¹, James Gore¹

¹Department of Internal Medicine, Ochsner Health, New Orleans, Louisiana.

Gastro Hep Advances

|July 21, 2025

Summary

This summary is machine-generated.

Resmetirom demonstrates good tolerability for metabolic dysfunction-associated steatohepatitis (MASH) fibrosis treatment. While most patients achieved insurance approval, delays and testing requirements posed access challenges.

Keywords:

Insurance Obstacles Medication Complications Prescription Disparities

More Related Videos

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Related Experiment Videos

Last Updated: Sep 14, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Remotely Supervised Transcranial Direct Current Stimulation: An Update on Safety and Tolerability

Published on: October 7, 2017

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Precision Implementation of Minimal Erythema Dose MED Testing to Assess Individual Variation in Human Inflammatory Response

Published on: October 3, 2019

Area of Science:

Hepatology
Pharmacology
Clinical Medicine

Background:

Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease.
Resmetirom is the first FDA-approved treatment for MASH.
Evaluating resmetirom's tolerability and access is crucial for patient care.

Purpose of the Study:

Assess resmetirom tolerability in MASH patients over 3 months.
Identify factors affecting medication access, including insurance and dispensing.
Analyze treatment outcomes and adverse events.

Main Methods:

Retrospective chart review of 113 MASH patients treated with resmetirom for at least 3 months.
Data collected on tolerability, adverse effects, liver enzymes, insurance coverage, and dispensing delays.
Analysis of patient outcomes and medication adherence.

Main Results:

Resmetirom showed good tolerability with low discontinuation rates (8.8%).
Common side effects included nausea, vomiting, and diarrhea (12.4% each).
Liver enzymes (AST, ALT, ALP) showed a decrease after 3 months of treatment.
24.1% of patients required insurance appeals, with 93.4% ultimately approved.
Average delay in prescription fill post-approval was 12.5 days.

Conclusions:

Resmetirom is a safe and well-tolerated MASH treatment in the short term.
Insurance approval is generally achievable, but appeals and dispensing delays are common.
Invasive fibrosis testing may be required for insurance approval, impacting timely access.